{"id":393292,"date":"2010-03-05T09:27:39","date_gmt":"2010-03-05T14:27:39","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.787"},"modified":"2010-03-05T09:29:50","modified_gmt":"2010-03-05T14:29:50","slug":"three-hcv-drug-candidates-proceed-to-phase-ii","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/393292","title":{"rendered":"Three HCV Drug Candidates Proceed to Phase II"},"content":{"rendered":"<p>Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.<\/p>\n<p>Abbott, Enanta moving Hepatitis C drug development<\/p>\n<p>March 2, 2010<\/p>\n<p>NEW YORK<\/p>\n<p>Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development.<\/p>\n<p>The companies said they will evaluate three potential hepatitis C drugs in Phase 2 clinical trials. <\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.businessweek.com\/ap\/financialnews\/D9E6J6M81.htm\">http:\/\/www.businessweek.com\/ap\/financialnews\/D9E6J6M81.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing. Abbott, Enanta moving Hepatitis C drug development March 2, 2010 NEW YORK Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development. The companies said they will evaluate three potential hepatitis C drugs [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-393292","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/393292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=393292"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/393292\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=393292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=393292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=393292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}